Pitfalls in patenting academic CAR-T cells therapy.

EXPERT OPINION ON THERAPEUTIC PATENTS(2023)

Cited 0|Views11
No score
Abstract
There is no one-size-fits-all solution in this matter and the medical evolution of this therapy will certainly bring out even more challenges. Comprehensive knowledge of the intellectual property, exposure to potential litigation, growing competition, and the high price of therapy, are strikingly relevant in the broader landscape. Future endeavors would be to take steps towards the harmonization of the CAR-T patenting procedure.
More
Translated text
Key words
Chimeric antigen receptor (CAR)-T cells,CAR-T cells,immunotherapy,patents,intellectual property
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined